Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

18,214 total articles

TalentAlly, a Subsidiary of Professional Diversity Network, Inc., Launches Next-Generation Career Fair Hiring Platform Powered by ByteCompute.ai

TalentAlly, a Subsidiary of Professional Diversity Network, Inc., Launches Next-Generation Career Fair Hiring Platform Powered by ByteCompute.ai

Professional Diversity Network, Inc. (Nasdaq: IPDN) announced that its subsidiary, TalentAlly, has launched a next-generation virtual hiring platform powered by ByteCompute.ai. The platform offers advanced features such as pre-event candidate targeting, real-time multi-channel engagement, and comprehensive analytics to improve recruiting outcomes a…

The Oncology Institute Names Minh Merchant Chief Legal Officer

The Oncology Institute Names Minh Merchant Chief Legal Officer

The Oncology Institute, a publicly traded oncology care provider, announced the hiring of Minh Merchant as Chief Legal Officer. Merchant brings over 20 years of healthcare legal expertise to oversee the company's legal, regulatory, compliance, and privacy functions, supporting its expansion as a leading value-based oncology group serving approximat…

Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer

Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer

Oncolytics Biotech Inc. announced a scheduled Type C meeting with the FDA to discuss a potential registrational single-arm pivotal study evaluating pelareorep combined with checkpoint inhibitors in second-line and later squamous cell anal carcinoma (SCAC) patients. This study aims to support full approval using objective response rate as the primar…

OneMedNet Announces Strong 2025 Financials and Advances AI-Driven iRWD™ powered by Palantir Foundry enabling Conversational Search on Real-Time Medical Data

OneMedNet Announces Strong 2025 Financials and Advances AI-Driven iRWD™ powered by Palantir Foundry enabling Conversational Search on Real-Time Medical Data

OneMedNet Corporation announced robust financial results for 2025, including a 329% year-over-year revenue increase driven by its AI-driven iRWD™ platform powered by Palantir Foundry. The company has reduced total liabilities by 74%, improved its equity position significantly, and secured promising pilot and subscription opportunities, projecting s…

Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement

Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement

Telix Pharmaceuticals Limited announced robust Q1 2026 financial results with 24% year-over-year revenue growth to $230 million and confirmed FY 2026 guidance between $950 million and $970 million. The company highlighted progress in its therapeutic pipeline, including successful completion of key safety objectives for its TLX591-Tx prostate cancer…

Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Celldex Therapeutics has closed its underwritten public offering of common stock, including full exercise of underwriters’ option, resulting in gross proceeds of approximately $345 million. The offering was conducted under an existing shelf registration with the SEC. The funds are aimed to support the advancement of Celldex's clinical-stage pipelin…

Jena Acquisition Corporation II Announces Non-Compliance with Section 802.01B of the NYSE Listed Company Manual which Requires the Company to Maintain a Minimum of 300 Public Stockholders

Jena Acquisition Corporation II Announces Non-Compliance with Section 802.01B of the NYSE Listed Company Manual which Requires the Company to Maintain a Minimum of 300 Public Stockholders

Jena Acquisition Corporation II, a US-listed blank check company on the NYSE, announced it is currently non-compliant with the NYSE's minimum public stockholder requirement of 300 shareholders. The company plans to submit a business plan to return to compliance within 18 months primarily by completing a de-SPAC transaction. During the cure period, …

Wix Announces Final Results of Modified Dutch Auction Tender Offer

Wix Announces Final Results of Modified Dutch Auction Tender Offer

Wix.com Ltd. successfully concluded its modified Dutch auction tender offer, purchasing 17.58 million shares (29.7% of outstanding shares) at $92.00 per share for approximately $1.617 billion. This substantial share buyback highlights the company's confidence in its long-term strategy and commitment to returning value to shareholders amid ongoing d…

ArcelorMittal has published a convening notice for its Annual General Meeting and Extraordinary General Meeting of shareholders to be held on 5 May 2026

ArcelorMittal has published a convening notice for its Annual General Meeting and Extraordinary General Meeting of shareholders to be held on 5 May 2026

ArcelorMittal has issued a convening notice for its Annual General Meeting and Extraordinary General Meeting on May 5, 2026. Key agenda items include the re-election of current board members, the nomination of a new director, Mr. Roy Harvey, former President and CEO of Alcoa, and renewal of board authorization to issue and cancel shares. Relevant d…

Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)

Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)

Denali Therapeutics announced Takeda's decision to terminate their collaboration on DNL593, a progranulin replacement therapy for frontotemporal dementia linked to GRN mutations. Denali will continue clinical development independently and plans to report Phase 1/2 study results by the end of 2026. The investigational therapy uses Denali's Transport…

Weight Watchers Announces Leadership Transition and Board Updates

Weight Watchers Announces Leadership Transition and Board Updates

WW International, Inc. announced the departure of CEO Tara Comonte and has established an Office of the CEO led by senior executives during the search for a permanent successor. The Board formed a Transition Committee to oversee leadership changes and governance matters. Additionally, Debra Cotter was appointed chief legal officer and secretary. Th…